Company Description
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States.
The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine.
The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc.
Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Country | United States |
IPO Date | Mar 21, 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 22 |
CEO | Peter Ludlum CMA, MBA |
Contact Details
Address: 99 Hayden Avenue Lexington, Massachusetts United States | |
Website | https://www.pulmatrix.com |
Stock Details
Ticker Symbol | PULM |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001574235 |
CUSIP Number | 74584P301 |
ISIN Number | US74584P3010 |
Employer ID | 46-1821392 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Peter Ludlum CMA, MBA | Interim Chief Executive Officer |
Dr. Alexander M. Klibanov Ph.D. | Founder |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 13, 2024 | 8-K | Current Report |
Nov 08, 2024 | ARS | Filing |
Nov 08, 2024 | DEF 14A | Filing |
Nov 08, 2024 | 10-Q | Quarterly Report |
Nov 08, 2024 | 8-K | Current Report |
Oct 08, 2024 | 8-K | Current Report |
Aug 13, 2024 | 10-Q | Quarterly Report |
Aug 13, 2024 | 8-K | Current Report |
Jul 19, 2024 | 8-K | Current Report |
May 29, 2024 | 8-K | Current Report |